Japanese researchers look set to have another option for biomarker analysis, after Thermo Fisher Scientific unveils plans for Tokyo research laboratory unit.
Research into the use of quadrupole resonance spectroscopy (QR) for non-invasive, non-destructive detection of counterfeits has been boosted by a grant.
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.
Indian contractor Terrene Pharma has filed a DMF for hard gelatin capsules with the US FDA, signalling its intention to expand in the world’s most lucrative drug market.
A group of Irish drug firms and banks plan to set up a “global pharmaceutical centre of excellence” (COE) that they believe will create 4,800 research, development and manufacturing jobs.
Encorium has bought Progenitor International Research, furthering efforts to fix its financial woes by focusing on vaccines, oncology and growth in emerging markets.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
GSK and Pfizer’s ViiV Healthcare JV says it will make its entire drug portfolio available to generics manufacturers and 80 per cent the global HIV-infected population.
Penn Pharma and Xcelience have formed an Xcelodose-focused joint venture to meet client demand in Europe and Asia for powder-in-capsule (PIC) services.
Applied Clinical Intelligence (ACI) has launched iCommittees to provide a platform to support sponsors’ needs for clinical endpoint adjudication and data monitoring committees (DMC).
CRL has said the WuXi buy could add up to $100m (€78m) in additional annual revenue and spoken of clients’ enthusiasm for the deal as its attempts to shore up investor support.
The Institute for OneWorld Health (iOWH) has moved one step closer to supplying a key component of a malaria treatment on an industrial scale as it revealed details of its latest activities to bring the ingredient to regions in short supply.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
InhibOx and the Cambridge Crystallographic Data Centre (CCDC) say new drug discovery services partnership is motivated by market need for CADD expertise.
The rapidly evolving Asian drug manufacturing sector represents both an opportunity and a challenge for the fine chemicals and molecules industry, according to SAFC president Gilles Cottier.
Ireland-based Firecrest Clinical says focusing on trial specific training and visits for principal investigators can speed recruitment, cut protocol deviations and produce cleaner data.
Quintiles is establishing its first Prime Site in Asia by entering into a strategic alliance with the University Malaya Medical Centre (UMMC) in Malaysia.
The opening of a New York office will help communicate Clintec’s global reach to US Pharmaceutical according to new associate director of US business operations, Susan Pavone.
Indian CROs Max Neeman International and QED Pharmaceutical Services have both added US Food and Drug Administration’s (FDA) CDISC compliance to their data management offering this month.
Suzhou Erye, a subsidiary of NeoStem Pharmaceutical, has passed inspection by the Chinese Food and Drug Administration (SFDA) meaning the company's new manufacturing facility will go ahead with the manufacture of penicillin and cephalosporin powder...
India’s oldest pharmaceutical company Alembic went one step closer to the biggest restructuring in its history as its board approved the demerging of its main pharmaceutical business into a separate subsidiary company, Alembic Pharma.
Sanofi-Aventis will build a new manufacturing plant in King Abdullah Economic City (KAEC) in Saudi Arabia through an agreement with the Emaar development company (ECC).
Tanabe Research Labs (TRL) has revealed details of its new San Diego facility in which the revised layout of the site allows a fresh focus on antibody and biological approaches to autoimmune diseases such as diabetes and rheumatoid arthritis.
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
New Gerresheimer CEO Uwe Roehrhoff wants the German firm to become the pharmaceutical and biopharmaceutical industry “first choice” partner for high-tech packaging.
US CRO Kendle has opened a new services centre in India, attracted by the country’s thriving contract research sector and favourable climate for clinical trials.
US drugmaker Merck & Co’s new deal with Adcock Ingram proves the FIFA football World Cup isn’t the only thing attracting people to South Africa this summer.
ViroPharma is seeking permission from the Food and Drug Administration (FDA) to increase production of Cinryze to an industrial scale as part of its ongoing expansion activities.
French drug maker Sanofi-Aventis continues to spearhead the fight for a more secure pharmaceutical supply chain by launching an anti-counterfeit medication initiative in Egypt.
Schott Pharmaceutical Packaging has revealed details of its US-based ready-to-fill syringe production line capabilities in a manufacturing sector that has traditionally been the strong hold of countries like Germany and France.
The role of the pharma industry in supporting the COE anti-counterfeiting treaty, which aims to criminalise activities, “cannot be underestimated”, according to a directorate member.
Nearly half of healthcare supply chain executives are planning to expand into emerging markets in the next 18 months, according to a UPS survey, but are concerned about the process.
The ACRO says greater regulatory harmonization, expansion of trial registries and clarification of liability issues are needed to address the “alarming” drop in number of investigators participating in trials in US and Europe
Parabolic Drugs will enter India’s CRAMS sector with new dedicated manufacturing facilities designed to attract “global innovator companies” enabling its business to grow in regulated markets.